Eli Lilly (LLY) Q4 Earnings and Revenues Beat Estimates

Core Insights - Eli Lilly (LLY) reported quarterly earnings of $7.54 per share, exceeding the Zacks Consensus Estimate of $6.99 per share, and up from $5.32 per share a year ago, representing an earnings surprise of +7.88% [1] - The company posted revenues of $19.29 billion for the quarter ended December 2025, surpassing the Zacks Consensus Estimate by 7.95%, compared to $13.53 billion in the same quarter last year [2] - Lilly has surpassed consensus EPS estimates three times over the last four quarters and topped revenue estimates four times during the same period [2] Future Outlook - The sustainability of the stock's price movement will depend on management's commentary during the earnings call and the earnings outlook for the coming quarters [3][4] - The current consensus EPS estimate for the next quarter is $6.96 on revenues of $16.75 billion, and for the current fiscal year, it is $33.24 on revenues of $77.52 billion [7] - The estimate revisions trend for Lilly was mixed ahead of the earnings release, resulting in a Zacks Rank 3 (Hold) for the stock, indicating expected performance in line with the market [6] Industry Context - The Large Cap Pharmaceuticals industry, to which Lilly belongs, is currently in the bottom 22% of over 250 Zacks industries, suggesting potential challenges ahead [8] - The performance of Lilly's stock may also be influenced by the overall outlook for the industry, as research indicates that the top 50% of Zacks-ranked industries outperform the bottom 50% by more than 2 to 1 [8]